评估3,4-二羟基-6-[18F]-氟-L-苯丙氨酸(18F-DOPA)PET与MRI在复发性胶质瘤患者中敏感性和特异性的前瞻性试验
该前瞻性研究纳入13例MRI怀疑复发性胶质瘤患者,比较18F-DOPA-PET与MRI增强(CE)的敏感性和特异性。37份标本组织病理分析显示,MRI CE敏感性52%、特异性50%,PET敏感性82%、特异性50%。T/N阈值>2.0时敏感性76%、特异性100%,SUVmax>1.36时敏感性94%、特异性75%。
要点
- 18F-DOPA-PET较MRI CE可视化复发性胶质瘤的空间分布具有更高的敏感性和特异性。
- MRI CE诊断复发性肿瘤的敏感性为52%,特异性为50%。
- PET诊断复发性肿瘤的敏感性为82%,特异性为50%。
核心结论
- 18F-DOPA-PET较MRI CE可视化复发性胶质瘤的空间分布可提供更高的敏感性和特异性。
研究设计与样本
- 前瞻性纳入13例MRI发现疑似复发性胶质瘤的患者,行18F-DOPA-PET和MRI用于神经外科手术规划。
- 从PET与MRI CE一致和不一致区域获取立体定向活检,所有活检均在T2/FLAIR信号高信号区域内。
- 基于组织病理学分析计算18F-DOPA-PET和CE的敏感性和特异性。
- 采用受试者工作特征曲线分析确定最佳肿瘤与正常组织(T/N)比值和SUVmax阈值。
主要发现
- 获得的37份标本中,51%显示MRI对比增强(M+),78%显示18F-DOPA-PET摄取(P+)。
- 影像学特征包括M-P-占16%、M-P+占32%、M+P+占46%、M+P-占5%。
- 活检组织病理学复查显示II级成分占16%、III级占43%、IV级占30%、无肿瘤占11%。
- MRI CE诊断复发性肿瘤的敏感性为52%,特异性为50%。
- PET诊断肿瘤的敏感性为82%,特异性为50%。
关键数值与推荐
- T/N阈值>2.0时,敏感性改变为76%,特异性为100%。
- SUVmax>1.36时,敏感性和特异性分别提高至94%和75%。
临床怎么用
- 未来研究将把18F-DOPA-PET纳入再程放疗靶区勾画以用于放疗规划。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-related changes can be difficult to differentiate from progressive glioma using MRI with contrast (CE). The purpose of this study is to compare the sensitivity and specificity of 18F-DOPA-PET and MRI in patients with recurrent glioma. Thirteen patients with MRI findings suspicious for recurrent glioma were prospectively enrolled and underwent 18F-DOPA-PET and MRI for neurosurgical planning. Stereotactic biopsies were obtained from regions of concordant and discordant PET and MRI CE, all within regions of T2/FLAIR signal hyperintensity. The sensitivity and specificity of 18F-DOPA-PET and CE were calculated based on histopathologic analysis. Receiver operating characteristic curve analysis revealed optimal tumor to normal (T/N) and SUVmax thresholds. In the 37 specimens obtained, 51% exhibited MRI contrast enhancement (M+) and 78% demonstrated 18F-DOPA-PET avidity (P+). Imaging characteristics included M-P- in 16%, M-P+ in 32%, M+P+ in 46% and M+P- in 5%. Histopathologic review of biopsies revealed grade II components in 16%, grade III in 43%, grade IV in 30% and no tumor in 11%. MRI CE sensitivity for recurrent tumor was 52% and specificity was 50%. PET sensitivity for tumor was 82% and specificity was 50%. A T/N threshold > 2.0 altered sensitivity to 76% and specificity to 100% and SUVmax > 1.36 improved sensitivity and specificity to 94 and 75%, respectively. 18F-DOPA-PET can provide increased sensitivity and specificity compared with MRI CE for visualizing the spatial distribution of recurrent gliomas. Future studies will incorporate 18F-DOPA-PET into re-irradiation target volume delineation for RT planning.
引用
- Youland RS, Pafundi DH, Brinkmann DH, et al. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol. 2018. PMID: 29330751. doi:10.1007/s11060-018-2750-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。